A New mRNA Flu Shot Is Closer to Approval—Should Adults 50+ Wait?
On June 18, 2026, an FDA advisory committee backed Moderna’s investigational mRNA flu vaccine for adults 50 and older—but the product is not approved yet. For most people, the safer practical choice is to get the recommended 2026–2027 flu shot when it’s available, then revisit updates after FDA’s final decision.
If you’re 50 or older and wondering whether to hold off for a new mRNA flu shot from Moderna, the practical answer is probably no. The vaccine moved a step closer on June 18, 2026, when an FDA advisory committee supported it—but advisory committee feedback is nonbinding and the shot is not yet available in the way licensed flu vaccines are.
For most adults, the best next step remains the same: get an age-appropriate flu vaccine for the 2026–2027 season when it becomes available in your area, and then follow updates after FDA’s final action.
What happened on June 18, 2026?
On June 18, 2026, FDA’s Vaccines and Related Biological Products Advisory Committee reviewed Moderna’s investigational mRNA flu vaccine for adults 50 to 64 and 65 and older. The committee’s recommendation is nonbinding, but Associated Press reported the panel voted that the benefits appear to outweigh the risks. AP also reported that FDA’s final decision was expected by early August 2026.
Who the vaccine was studied in
FDA’s detailed review materials describe a split analysis across two age groups. For adults 50 to 64, FDA emphasized one-season efficacy data. For adults 65 and older, FDA focused more on immune-response evidence and noted that a required confirmatory study would come after approval. The pivotal phase 3 program described in the FDA materials enrolled tens of thousands of adults age 50 and older.
What the evidence showed for adults 50–64
In FDA’s briefing materials, the key efficacy evidence for adults 50 to 64 is based on one flu season of data from the phase 3 trial. FDA documents report RT-PCR–confirmed influenza-like illness occurred in 2.0% of people who received the mRNA vaccine and 2.8% of people who received a licensed comparator, corresponding to a reported relative vaccine efficacy of 26.6%. Encouraging, but it’s still only one season, and flu vaccine performance can vary by season depending on which strains circulate.
What the evidence showed for adults 65+
For adults 65 and older, FDA’s framing placed more weight on immune-response data compared with a flu vaccine already used/preferred for many older adults, along with the plan for a required confirmatory study after an initial authorization/approval pathway.
What the safety review found (high level)
FDA’s review and supporting trial reporting describe more short-term side effects with the investigational mRNA vaccine than with comparator flu shots—commonly things like injection-site pain, fatigue, headache, and muscle aches. FDA’s materials also describe that serious adverse events and other monitored categories were not clearly imbalanced in a way that established a specific vaccine-related safety signal.
As with any vaccine authorization process, uncertainty remains—especially for rare events that may be hard to detect until broader use and longer follow-up.
Should adults 50+ wait for this new mRNA shot?
For most people, probably not. Waiting only helps if the new product is both approved and widely available before your usual vaccination window—and if coverage and costs are favorable. Those practical details are still uncertain while FDA’s final decision is pending.
Meanwhile, CDC and major U.S. clinical guidance continue to support getting a recommended flu vaccine each year. Adults 65 and older are often offered or steered toward age-preferred options (such as high-dose, recombinant, or adjuvanted products) when available—but if those specific options aren’t obtainable, getting an age-appropriate licensed flu vaccine is still the goal.
What readers can do now
- Plan to get the 2026–2027 flu vaccine when it’s available where you live.
- Follow age-appropriate recommendations from trusted clinical guidance (including CDC season guidance and adult immunization schedules).
- If you’re 65 or older, ask which age-preferred flu vaccine options are available through your pharmacy or clinician, and choose an age-appropriate licensed option.
- If you’re specifically interested in Moderna’s mRNA vaccine, watch for updates after FDA’s final decision rather than assuming it will be ready in time.
What’s still unknown
- Final FDA outcome: whether FDA grants approval/authorization as proposed and exactly how it may be structured across age groups.
- Real-world comparative performance: how this vaccine compares with existing flu vaccines once used outside clinical trials.
- Availability and coverage: whether the product will be broadly accessible this season and how insurance coverage or out-of-pocket costs may vary.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
